Janssen Halts Clinical Studies of Alzheimer's Candidate

Johnson & Johnson’s Janssen Biotech said it will halt two clinical studies assessing its Alzheimer’s disease candidate atabecestat (JNJ-54861911), citing an unfavorable risk–benefit profile for the β-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor.Janssen said it will stop screening, randomization, and dosing of atabecestat in its Phase IIb/III EARLY trial ( NCT02569398 ) assessing the drug in late-onset preclinical-stage Alzheimer’s, as well as i